- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03876223
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
Women's Ischemia Syndrome Evaluation (WISE) Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure With Preserved Ejection Fraction (HFpEF)
Study Overview
Status
Detailed Description
Coronary microvascular dysfunction (CMD) due to changes in the function and structure of coronary microcirculation in the absence of obstructive coronary artery disease (CAD) is poorly understood. Ischemia with no obstructive CAD (INOCA) and myocardial infarction with no obstructive CAD (MINOCA) are increasingly observed in women and men.
Once established, the investigators will be well positioned to aggressively target identified mechanistic targets in a specific well-characterized at-risk population, with the primary goal of preventing progression to HFpEF.
To address this novel hypothesis, the investigators propose the following Specific Aims:
Aim 1: Test the hypothesis that CMD-related ischemia contributes to myocellular damage and impaired ventricular relaxation. CMD will be measured directly, using our established intracoronary pharmacological vasoactive protocol, in subjects with signs/symptoms of ischemia but no obstructive CAD. In our labs (>420 patients), ~60% of those tested have evidence for CMD. All subjects will perform provocative stress testing with isometric handgrip - chosen for its unique ability to increase myocardial afterload and myocardial oxygen demand - while myocardial ischemia will be assessed directly through invasive simultaneous arterial and coronary sinus/great cardiac vein oxygen tension and lactate measurements, and continuous ECG's recordings. Left ventricular function will be directly assessed using Millar-catheter LV pressure-volume loops (perfected in our lab over the past 24 months). Stress-induced myocellular damage will be directly measured by coronary sinus/great cardiac vein hs-cTnI.
Aim 2: Test the hypothesis that CMD-related ischemic myocellular damage contributes to LV diastolic dysfunction progression. Subjects from Aim 1 will also undergo comprehensive cardiac magnetic resonance imaging (CMRI) at enrollment and 1-2 years later. The investigators will evaluate CMRI LV perfusion, myocardial scar, diffuse fibrosis, LV remodeling, and diastolic function. The investigatorswill leverage the strengths and resources of our world-renowned proteomics core to establish evidence of chronic myocellular damage using prospectively repeated ambulatory hs-cTnI determinations.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Nicole Tovar
- Phone Number: 310-248-6960
- Email: nicole.tovar@cshs.org
Study Contact Backup
- Name: Lorena Guzman
- Phone Number: 3102486960
- Email: lorena.guzman@cshs.org
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai Medical Center
-
Contact:
- C. Noel Bairey Merz, MD
- Phone Number: 310-248-6960
- Email: noel.baireymerz@cshs.org
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Recruiting
- University of Florida
-
Contact:
- Eileen Handberg, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion:
- 180 symptomatic men and women undergoing invasive coronary angiography for suspected ischemia with no obstructive CAD, defined as ≥50% luminal diameter stenosis in ≥1 epicardial coronary artery.
- Preserved left ventricular ejection fraction (EF) ≥45%
- Be > 18 years old
- Be able to meet the requirement for a cardiac MRI, which means no metal devices in your chest, no claustrophobia and no angioedema
- Be competent to give informed consent
Exclusion:
- Subjects with severe or chronic kidney disease (CKD) with GFR<405 or acute kidney injury
- Subjects with allergy to animal dander will be excluded since imaging will be done in BIRI (BIRI scanners are also used to image animals).
- Subjects who have had four or more prior previous gadolinium contrast scans
- Allergy/ hypersensitivity to adenosine, gadolinium, aminophylline or regadenoson
- Second- or third-degree A-V block
- Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker)
- Subjects with mild to severe asthma
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CMR imaging
Time Frame: Baseline, Annual follow up
|
Change from Baseline at 1 year follow up will be assessed.
|
Baseline, Annual follow up
|
Rest-stress Millar pressure-volume measurement
Time Frame: Baseline
|
LV diastolic function will be measured using LV end-diastolic pressure, minimal rate of LV pressure change (dP/dtmin).
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Questionnaire
Time Frame: Baseline, 6 week, quarterly(year 1) and annual follow up
|
Symptom History Questionnaire.
Change from Baseline at each visit will be measure.
There is no scale ranges for this questionnaire.
This questionnaire results in raw data that is not calculated into a score or scale.
|
Baseline, 6 week, quarterly(year 1) and annual follow up
|
Questionnaire WISE Symptoms History
Time Frame: Baseline, quarterly(year 1) and annual follow up
|
Detailed information on chest pain symptoms will include the WISE female angina questionnaire. Change from Baseline at each visit will be measure. There is no scale ranges for this questionnaire. This questionnaire results in raw data that is not calculated into a score or scale. |
Baseline, quarterly(year 1) and annual follow up
|
SEATTLE ANGINA QUESTIONNAIRE
Time Frame: Baseline, 6 week and annual follow up
|
The SAQ quantifies patients' physical limitations caused by angina, the frequency of and recent changes in their symptoms, their satisfaction with treatment, and the degree to which they perceive their disease to affect their quality of life. Each scale is transformed to a score of 0 to 100. A higher score means better control of chest pain, chest tightness, angina, or shortness of breath. Change from Baseline at each visits will be measure. |
Baseline, 6 week and annual follow up
|
Duke Activity Status Inventory (DASI)
Time Frame: Baseline, 6 week and annual follow up
|
It is a self-administered questionnaire that measures a patient's functional capacity. Change from Baseline at each visit will be measure. Maximum response is a total of 16.7 while minimum is 0. |
Baseline, 6 week and annual follow up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: C. Noel Bairey Merz, MD, FACC, Cedars-Sinai Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 54999
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Microvascular Dysfunction
-
Cedars-Sinai Medical CenterActive, not recruitingMicrovascular Coronary DysfunctionUnited States
-
Peking University First HospitalRecruitingCoronary Microvascular DysfunctionChina
-
Amir LermanCompletedCoronary Microvascular DysfunctionUnited States
-
Ge JunboRainMed MedicalCompleted
-
Mette ZanderHvidovre University HospitalCompletedCoronary Microvascular DysfunctionDenmark
-
Lisata Therapeutics, Inc.TerminatedCoronary Microvascular Disease | Coronary Microvascular Dysfunction | Microvascular Coronary Artery DiseaseUnited States
-
Cedars-Sinai Medical CenterWithdrawnMicrovascular Coronary DysfunctionUnited States
-
Medstar Health Research InstituteRecruiting
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
Spanish Society of CardiologyRecruitingAngina, Stable | Coronary Microvascular Disease | Coronary Microvascular DysfunctionSpain